17 December 2024 in Journal of Infection and Public Health
During the COVID-19 pandemic, seasonal influenza virus circulation was heavily suppressed worldwide. In Australia, since the virus re-emerged in 2022, shifts in seasonal influenza patterns have been observed. Both the 2022 and 2023 seasons started earlier than pre-pandemic norms and were categorised as moderate to severe, highlighting the renewed importance of prevention strategies for seasonal influenza. We analysed influenza notification data from the Australian National Notifiable Diseases Surveillance System (2012-2022) and virological surveillance data from the FluNet database (2012-2023). Using generalised additive models, we compared predicted weekly influenza case counts during 2020-2022 with observed counts. Epidemic weeks were detected using a negative binomial threshold, and epidemic onset was estimated with a Bayesian Poisson count detection algorithm. Trends in epidemic magnitude and onset timing across influenza virus types and subtypes were compared for pre-, during, and post-COVID-19 periods. Seasonal influenza activity was nearly absent in 2020 and 2021 but rebounded significantly in 2022 and 2023. Epidemic detection confirmed suppressed seasonal influenza circulation during the pandemic. While influenza A subtypes returned to pre-pandemic onset timings in 2022, influenza B exhibited a significantly delayed onset. The 2022 and 2023 seasons were moderate to severe, with earlier-than-average season starts, underscoring the ongoing changes in influenza dynamics post-pandemic. This study provided a detailed analysis of the disruptions and subsequent shifts in seasonal influenza patterns in Australia during and after the COVID-19 pandemic. The rapid resurgence of influenza activity in 2022 and 2023, combined with altered onset timings, highlights the importance of ongoing surveillance and adaptive forecasting models to address the evolving complexity of influenza epidemiology in the post-pandemic era.
8 October 2021 in PLOS Neglected Tropical Diseases
13 August 2026 in Journal of Infection and Public Health
COVID-19 non-pharmaceutical interventions disrupted respiratory syncytial virus (RSV) transmission globally. In Australia, RSV surged back after restrictions eased, whether this reflected immunity debt repayment or epidemic amplification is untested. We conducted a national interrupted time-series analysis using Australian Institute of Health and Welfare hospitalisation data from financial years (FY) 2010/11-2023/24. The primary outcome was RSV-attributable fraction (RSV-AF) of bronchiolitis in infants and children 1-4 years. Pre-pandemic counterfactual trends were estimated by linear extrapolation of FY2010/11-2019/20 training data, this was appropriate given the stable, low-gradient pre-pandemic RSV-AF trends in both groups. For adults ≥ 65 years, a flat counterfactual (pre-pandemic mean) to bound estimates where a secular ascertainment rise made linear extrapolation inappropriate. Formal amplification test: one-sided Z-test of whether rebound exceeded suppression deficit. Influenza-attributable fraction used as a pathogen-specific comparator to isolate RSV from general respiratory rebound. Non-RSV bronchiolitis decomposed to rule out general post-pandemic denominator effects. In infants, pre-pandemic RSV-AF was 32.3% (SD 1.8%). In FY 2022/23, it reached 52.0% (z = 10.78; p < 0.001), 19.7 %age points above the pre-pandemic upper control limit. RSV bronchiolitis accounted for 95.1% of the total bronchiolitis increase; non-RSV bronchiolitis remained below counterfactual. In 1-4-year-olds, RSV-AF of bronchiolitis reached 49.1%, against a pre-pandemic mean of 23.2%. Formal testing found rebound significantly exceeded deficit in infants, 1-4-year-olds, and 5-19-year-olds (all p < 0.001). Adults 20-64 years showed significantly incomplete discharge (β=0.71, meaning the rebound recovered only 71% of the accumulated suppression deficit; p = 0.020). The RSV rebound in young children significantly exceeded the suppression deficit, consistent with epidemic amplification potentially reflecting accumulated primary-infection susceptibility in unvaccinated cohorts. After explanations (testing intensity, admission thresholds, demography, and coding changes) were accounted for. The FY2022/23 baseline provides the pre-vaccination reference for evaluating Australia's RSV immunisation program.